|
Regimen
|
|
Gemcitabine
|
8 (40.0%)
|
0
|
|
Vinorelbine
|
6 (30.0%)
|
0
|
|
Docetaxel
|
5 (25.0%)
|
0
|
|
Pemetrexed
|
1 (5.0%)
|
0
|
|
Carboplatin + weekly paclitaxel
|
0
|
9 (81.8%)
|
|
Carboplatin + gemcitabine
|
0
|
1 (9.1%)
|
|
Carboplatin + S-1
|
0
|
1 (9.1%)
|
|
Response rate (%)
|
0
|
45.4%
|
|
Disease control rate (%)
|
55.0%
|
54.5%
|
|
Progression free survival (month)
|
2.87 [0.60–7.27]
|
5.43 [1.58–8.07]
|
|
Number of treatment cycles
|
2.00 [1.00–2.25]
|
3.00 [1.00–4.00]
|
|
Early termination (only 1 cycle) (%)
|
7 (35.0%)
|
4 (36.4%)
|
|
Cause of cessation
|
|
Adverse event
|
11 (55.0%)
|
4 (36.4%)
|
|
Deterioration of physical condition
|
5 (25.0%)
|
0
|
|
Completion of 4–6 cycles
|
0
|
5 (45.5%)
|
|
Progressive disease
|
3 (15.0%)
|
1 (9.1%)
|
|
Patient’s request
|
1 (5.0%)
|
1 (9.1%)
|
